Genvor Inc (GNVR) officer discloses preferred stock holdings and conversions

Rhea-AI Filing Summary

Genvor Inc. director and Chief Research Officer Dr. Jesse Jaynes filed an initial Form 3 reporting his beneficial ownership in the company. As of August 25, 2023, he and his spouse jointly owned 476,762 shares of Series B Preferred Stock, which are convertible at the holder’s election into 10 shares of common stock each, for a total of 4,767,620 issuable common shares. He may also be deemed the beneficial owner of 200,000 additional Series B Preferred shares held by Jaynes Investment LLC, similarly convertible into 2,000,000 common shares. In addition, he owns 3 shares of Series A Preferred Stock, each convertible into 1 share of common stock.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Jaynes Jessee M

Role Chief Research Officer

Type	Security	Shares	Price	Value
holding	Series B Preferred Stock	--	--	--
holding	Series B Preferred Stock	--	--	--
holding	Series B Preferred Stock	--	--	--

Holdings After Transaction: Series B Preferred Stock — 4,767,620 shares (Direct); Series B Preferred Stock — 2,000,000 shares (Indirect, Jaynes Investment LLC)

Footnotes (1)

1. As of August 25, 2023, the date that the issuer filed its registration statement on Form 8-A, Dr. Jaynes and his spouse, Mary Jaynes, jointly owned 476,762 shares of Series B Preferred Stock. Each share of Series B Preferred Stock is convertible at the election of the holder into 10 shares of common stock, such that 4,767,620 shares of common stock are issuable upon conversion of the Jaynes' Series B Preferred Stock. Dr. Jaynes may be deemed to be the beneficial owner of 200,000 shares of the issuer's Series B Preferred Stock, held in the name of Jaynes Investment LLC as of August 25, 2023. Each share of Series B Preferred Stock is convertible at the election of the holder into 10 shares of common stock, such that 2,000,000 shares of common stock are issuable upon conversion of Jaynes Investment LLC's Series B Preferred Stock. As of August 25, 2023, Dr. Jaynes owns 3 shares of the issuer's Series A Preferred Stock. Each share of Series A Preferred Stock is convertible at the election of the holder into 1 share of common stock, such that 3 shares of common stock are issuable upon conversion of Dr. Jaynes' Series A Preferred Stock.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Jaynes Jessee M

(Last) (First) (Middle)

1550 W HORIZON RIDGE PKWY

STE R #3040

(Street)

HENDERSON NV 89012

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
08/25/2023

3. Issuer Name and Ticker or Trading Symbol
Genvor Inc [ GNVR ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Research Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series B Preferred Stock(1)	(1)	(1)	Common Stock(1)	4,767,620(1)	(1)	D(1)
Series B Preferred Stock(2)	(2)	(2)	Common Stock(2)	2,000,000(2)	(2)	I(2)	Jaynes Investment LLC
Series B Preferred Stock(3)	(3)	(3)	Common Stock(3)	3(3)	(3)	D

Explanation of Responses:

1. As of August 25, 2023, the date that the issuer filed its registration statement on Form 8-A, Dr. Jaynes and his spouse, Mary Jaynes, jointly owned 476,762 shares of Series B Preferred Stock. Each share of Series B Preferred Stock is convertible at the election of the holder into 10 shares of common stock, such that 4,767,620 shares of common stock are issuable upon conversion of the Jaynes' Series B Preferred Stock.

2. Dr. Jaynes may be deemed to be the beneficial owner of 200,000 shares of the issuer's Series B Preferred Stock, held in the name of Jaynes Investment LLC as of August 25, 2023. Each share of Series B Preferred Stock is convertible at the election of the holder into 10 shares of common stock, such that 2,000,000 shares of common stock are issuable upon conversion of Jaynes Investment LLC's Series B Preferred Stock.

3. As of August 25, 2023, Dr. Jaynes owns 3 shares of the issuer's Series A Preferred Stock. Each share of Series A Preferred Stock is convertible at the election of the holder into 1 share of common stock, such that 3 shares of common stock are issuable upon conversion of Dr. Jaynes' Series A Preferred Stock.

	/s/ Dr. Jesse Jaynes	12/05/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does Genvor Inc (GNVR) disclose about Dr. Jesse Jaynes’s role?

Dr. Jesse Jaynes is reported as a director of Genvor Inc and serves as an officer with the title of Chief Research Officer.

What Series B Preferred Stock does Dr. Jaynes report owning in Genvor Inc (GNVR)?

As of August 25, 2023, Dr. Jaynes and his spouse jointly owned 476,762 shares of Series B Preferred Stock, each share convertible at the holder’s election into 10 shares of Genvor common stock.

How many Genvor (GNVR) common shares are issuable from Dr. Jaynes’s jointly owned Series B Preferred Stock?

The 476,762 jointly owned Series B Preferred shares are convertible into 4,767,620 shares of common stock at the holder’s election.

What indirect Series B Preferred Stock interest does Jaynes Investment LLC hold in Genvor (GNVR)?

Dr. Jaynes may be deemed the beneficial owner of 200,000 shares of Series B Preferred Stock held in the name of Jaynes Investment LLC, convertible into 2,000,000 shares of common stock at the holder’s election.

What Series A Preferred Stock holdings does Dr. Jaynes report in Genvor Inc (GNVR)?

As of August 25, 2023, Dr. Jaynes owns 3 shares of Series A Preferred Stock, each convertible at the holder’s election into 1 share of common stock, for a total of 3 issuable common shares.

Is the Genvor (GNVR) Form 3 filed by one or multiple reporting persons?

The form is indicated as being filed by one reporting person, reflecting Dr. Jaynes’s beneficial ownership, including interests held through Jaynes Investment LLC.